2011年和2012年从中国11家教学医院收集的372株革兰氏阴性杆菌对头孢他啶-阿维巴坦和氨曲南-阿维巴坦的体外活性。
In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.
作者信息
Wang Xiaojuan, Zhang Feifei, Zhao Chunjiang, Wang Zhanwei, Nichols Wright W, Testa Raymond, Li Henan, Chen Hongbin, He Wenqiang, Wang Qi, Wang Hui
机构信息
Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
出版信息
Antimicrob Agents Chemother. 2014;58(3):1774-8. doi: 10.1128/AAC.02123-13. Epub 2013 Dec 16.
Abstract
Ceftazidime-avibactam, aztreonam-avibactam, and comparators were tested by reference broth microdilution against 372 nonrepetitive Gram-negative bacilli (346 unselected plus 26 selected meropenem-nonsusceptible Enterobacteriaceae isolates) collected from 11 teaching hospitals in China in 2011 and 2012. Meropenem-nonsusceptible isolates produced extended-spectrum β-lactamases (ESBLs; e.g., CTX-M-14/3), AmpCs (e.g., CMY-2), and/or carbapenemases (e.g., KPC-2 and NDM-1). Avibactam potentiated the activity of ceftazidime against organisms with combinations of ESBLs, AmpCs, and KPC-2. Aztreonam-avibactam was active against all β-lactamase producers (including producers of NDM-1 and IMP-4/8) except blaOXA-containing Acinetobacter baumannii and some Pseudomonas aeruginosa isolates.
摘要
采用参考肉汤微量稀释法，对2011年和2012年从中国11家教学医院收集的372株非重复性革兰阴性杆菌（346株未筛选菌株加26株筛选出的美罗培南不敏感肠杆菌科分离株）进行了头孢他啶-阿维巴坦、氨曲南-阿维巴坦及对照药物的测试。美罗培南不敏感分离株产生超广谱β-内酰胺酶（ESBLs，如CTX-M-14/3）、AmpC酶（如CMY-2）和/或碳青霉烯酶（如KPC-2和NDM-1）。阿维巴坦增强了头孢他啶对产ESBLs、AmpC酶和KPC-2组合的菌株的活性。氨曲南-阿维巴坦对所有β-内酰胺酶产生菌（包括产NDM-1和IMP-4/8的菌株）均有活性，但对含blaOXA的鲍曼不动杆菌和一些铜绿假单胞菌分离株除外。
相似文献
1
In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.
Antimicrob Agents Chemother. 2014;58(3):1774-8. doi: 10.1128/AAC.02123-13. Epub 2013 Dec 16.
2
Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
Antimicrob Agents Chemother. 2014;58(3):1684-92. doi: 10.1128/AAC.02429-13. Epub 2013 Dec 30.
3
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):215-21. doi: 10.1128/AAC.01559-15. Print 2016 Jan.
4
Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01814-18. Print 2019 Apr.
5
In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.
Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.
6
Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.02569-17. Print 2018 Jul.
7
In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
Antimicrob Agents Chemother. 2015 Dec;59(12):7842-6. doi: 10.1128/AAC.02019-15. Epub 2015 Sep 21.
8
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
9
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
10
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01045-17. Print 2017 Nov.
引用本文的文献
1
In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Antibiotics (Basel). 2023 Sep 29;12(10):1493. doi: 10.3390/antibiotics12101493.
2
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
J Antimicrob Chemother. 2023 May 3;78(5):1191-1194. doi: 10.1093/jac/dkad061.
3
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
4
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
BMC Microbiol. 2022 Oct 1;22(1):234. doi: 10.1186/s12866-022-02644-5.
5
Panorama of Bacterial Infections Caused by Epidemic Resistant Strains.
Curr Microbiol. 2022 Apr 30;79(6):175. doi: 10.1007/s00284-022-02875-9.
6
Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review.
Drugs. 2022 Mar;82(4):407-438. doi: 10.1007/s40265-022-01676-5. Epub 2022 Mar 14.
7
In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates.
Antibiotics (Basel). 2021 Dec 5;10(12):1492. doi: 10.3390/antibiotics10121492.
8
Activity Comparison of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China.
Front Cell Infect Microbiol. 2021 Nov 25;11:780365. doi: 10.3389/fcimb.2021.780365. eCollection 2021.
9
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.
10
In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Isolates from South Korea.
Antibiotics (Basel). 2020 Dec 15;9(12):912. doi: 10.3390/antibiotics9120912.
本文引用的文献
1
Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Antimicrob Agents Chemother. 2013 Jul;57(7):3299-306. doi: 10.1128/AAC.01989-12. Epub 2013 May 6.
2
Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.
Antimicrob Agents Chemother. 2013 Apr;57(4):1982-8. doi: 10.1128/AAC.02436-12. Epub 2013 Feb 4.
3
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
Drugs. 2013 Feb;73(2):159-77. doi: 10.1007/s40265-013-0013-7.
4
New β-lactam-β-lactamase inhibitor combinations in clinical development.
Ann N Y Acad Sci. 2013 Jan;1277:105-14. doi: 10.1111/nyas.12010.
5
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. doi: 10.1073/pnas.1205073109. Epub 2012 Jul 2.
6
In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.
Antimicrob Agents Chemother. 2012 Mar;56(3):1606-8. doi: 10.1128/AAC.06064-11. Epub 2012 Jan 3.
7
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Int J Antimicrob Agents. 2012 Jan;39(1):86-9. doi: 10.1016/j.ijantimicag.2011.09.012. Epub 2011 Oct 29.
8
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors.
Curr Opin Microbiol. 2011 Oct;14(5):550-5. doi: 10.1016/j.mib.2011.07.026. Epub 2011 Aug 11.
9
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).
Antimicrob Agents Chemother. 2011 Jun;55(6):2992-4. doi: 10.1128/AAC.01696-10. Epub 2011 Mar 21.
10
Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.
Antimicrob Agents Chemother. 2011 May;55(5):2434-7. doi: 10.1128/AAC.01722-10. Epub 2011 Feb 28.
Zotero 插件